Business and People News
The latest industry happenings from the past month, all in one place.
People News
AG Mednet has named Brian Zabin as Chief Operating Officer.
Illingworth Research Group has hired Chris Wells as their new director of patient concierge services.
Business News
Crucial Data Solutions, Inc.(CDS) has reported 42% revenue growth in 1H-2020 vs. 1H-2019.
Clinerion has activated a second verification step during the sign-in process to protect Patient Network Explorer user accounts.
Europital has announced it is opening a UK site.
Panthera, North London
Panthera continues to expand its network of UK clinical trial sites with a new site in North London.
European Centre for Clinical Research Training (ECCRT) has been selected as a premium provider for continuous online learning by IDDI.
Recognition
Almac Group has announced the organization will donate £250,000 to 33 charities globally to support their work in the wake of COVID-19.
Inato announced the participation of over 300 clinical trial research sites in its global marketplace.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
